Everything below concerns AOD-9604. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-11-13. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
== External links == "An Evening with Caballo Blanco". Made to Run. October 29, 2009. Archived from the original (video) on April 6, 2012. "Copper Canyon with a Man Called Horse". McDougall, Christopher (April 3, 2012). "Running Community Mourning Loss of Micah True" (video). Imus in the Morning. Fox News. "Run for Your Life! At a comfortable pace, and not too far" (video). TEDxUMKC. Nov 27, 2012. Trivax, Justin E.; McCullough, Peter A. (January 4, 2012). "Phidippides Cardiomyopathy: A Review and Case Illustration". Clin Cardiol. 35 (2): 69–73. doi:10.1002/clc.20994. PMC 6652719. PMID 22222888. 11th Annual Ultramarathon "Run Free - The True Story of Caballo Blanco" (Video). 14 July 2014 – via YouTube. Boxing record for Micah True from BoxRec (registration required)
Colin Stagg has been through a version of justice, albeit truncated, and he has been found not guilty. But I wonder whether he can actually say hand on heart that he believes people will meet him in the street and believe that. I do not believe the system served anybody that particular day. After Stagg's acquittal, Pedder took early retirement from the police. He later faced corruption charges, but the case was thrown out by the judge in a pre-trial hearing on the grounds of insufficient evidence.
=== Global health research === Sarkar led a team of international scientists investigating naturally occurring arsenic and other toxic metals throughout South- and Southeast Asia. In his early research in Bangladesh, Sarkar identified a small child with advanced signs of arsenic poisoning, an observation that motivated extensive research in this region. Discovery Canada Television produced an hour-long documentary focusing on Sarkar's work on this devastating health crisis in Bangladesh. Sarkar's team discovered that arsenic is not the only toxic metal contaminating the groundwater; other toxic metals such as manganese, lead, chromium, and uranium are also present in groundwater. They produced heat maps of arsenic and other toxic metals in Bangladesh and West Bengal (India) groundwater, identifying areas where contamination is of special concern. Their investigation was further extended to the neighboring country of Myanmar (Burma), which has a similar geology, and where they found high concentrations of many of the same toxic metals in groundwater. Sarkar's team also carried out field work in Kathmandu, Nepal, in 2015. In addition, the team called for the WHO to re-evaluate its guidelines for many toxic substances in drinking water based on their health hazards. Sarkar's team stressed that multiple metal contamination of groundwater is an issue of global concern, and the risks may be further magnified by climate change.
Exposure to siliceous dusts in the ceramics industry is reduced by either processing and using the source materials as aqueous suspension or as damp solids, or by the use of dust control measures such as local exhaust ventilation. These have been mandated by legislation, such as The Pottery (Health and Welfare) Special Regulations 1950. The Health and Safety Executive in the UK has produced guidelines on controlling exposure to respirable crystalline silica in potteries, and the British Ceramics Federation provide, as a free download, a guidance booklet. Archived 2023-04-19 at the Wayback Machine
Sources: en.wikipedia.org
inert (of a chemical species) Stable and chemically unreactive; or thermodynamically non-labile, decomposing at a slow or negligible rate. Examples of inert species include the noble gases, which are stable in their naturally occurring forms because their outermost electron shells are filled with as many electrons as possible, making them broadly resistant to the loss or gain of electrons.
=== YqjD === YqjD is an inner membrane protein specific to stationary phase. It binds to 70S and 100S ribosomes and has been proposed as of 2018 to mediate the localization (moving) of hibernating ribosomes to the cell membrane. While cells lacking YqjD do not have altered growth rates of ribosome composition, artificially high levels of it quickly halts growth depending on the protein's ribosome-binding capability.
Many terms have been used in the literature to describe sets of elements that behave similarly. The group names alkali metal, alkaline earth metal, triel, tetrel, pnictogen, chalcogen, halogen, and noble gas are acknowledged by IUPAC; the other groups can be referred to by their number, or by their first element (e.g., group 6 is the chromium group). Some divide the p-block elements from groups 13 to 16 by metallicity, although there is neither an IUPAC definition nor a precise consensus on exactly which elements should be considered metals, nonmetals, or semi-metals (sometimes called metalloids). Neither is there a consensus on what the metals succeeding the transition metals ought to be called, with post-transition metal and poor metal being among the possibilities having been used. Some advanced monographs exclude the elements of group 12 from the transition metals on the grounds of their sometimes quite different chemical properties, but this is not a universal practice and IUPAC does not presently mention it as allowable in its Principles of Chemical Nomenclature. The lanthanides are considered to be the elements La–Lu, which are all very similar to each other: historically they included only Ce–Lu, but lanthanum became included by common usage. The rare earth elements (or rare earth metals) add scandium and yttrium to the lanthanides. The actinides are considered to be the elements Ac–Lr (historically Th–Lr), although variation of properties in this set is much greater than within the lanthanides.
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.